Format
Items per page
Sort by

Send to:

Choose Destination

Results: 6

Cited In for PubMed (Select 9258908)

1.

Tau as a therapeutic target in neurodegenerative disease.

Himmelstein DS, Ward SM, Lancia JK, Patterson KR, Binder LI.

Pharmacol Ther. 2012 Oct;136(1):8-22. doi: 10.1016/j.pharmthera.2012.07.001. Epub 2012 Jul 10. Review.

2.

Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model.

Krishnamurthy PK, Deng Y, Sigurdsson EM.

Front Psychiatry. 2011 Oct 21;2:59. doi: 10.3389/fpsyt.2011.00059. eCollection 2011.

3.

Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

Sigurdsson EM.

Curr Alzheimer Res. 2009 Oct;6(5):446-50. Review.

4.
5.

Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice.

Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T.

Am J Pathol. 2001 Aug;159(2):439-47.

6.

Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer.

Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS, Yan SD, Stern D, Schmidt AM, Frangione B, Zlokovic BV.

J Clin Invest. 1998 Aug 15;102(4):734-43.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk